Navigation Links
Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
Date:6/2/2009

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that additional results from its North American Phase 3 clinical study of fidaxomicin in patients with Clostridium difficile infection (CDI) were presented today by clinical investigator, Mark A. Miller, M.D., at the Digestive Disease Week 2009 conference in Chicago.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

The additional data presented today for the first time focused on other patient risk factors believed to be predictive of CDI recurrence following treatment. These risk factors include serum albumin levels, white blood cell (WBC) count and temperature, and non-BI (NAP1/027) strains. The data showed that fidaxomicin overall demonstrated a lower recurrence rate compared to oral vancomycin (Vancocin(R)) regardless of albumin levels, WBC count and temperature, as well as for patients with non-BI (NAP1/027) strains. Vancocin is currently the only FDA approved therapy for CDI.

Recurrence Rates by Subgroup (per protocol)

    -------------------------------------------------------------------------
    Risk Factors                         Fidaxomicin     Vancocin(R) capsules
                                         (200mg bid)         (125mg qid)
    -------------------------------------------------------------------------
    White Blood Cell Count /Temp
    -------------------------------------------------------------------------
    WBC < 15,000 uL and Temp
     < 38 degrees C                     10.7% (17/159)      22.4% (35/156)
    WBC 15-25,000 uL or Temp 38
     degrees - 39 degrees C             12.0% (3/25)        20.0% (6/30)
    WBC > 25,000 uL or Temp
   
'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... DIEGO , Sept. 16, 2014  Biocom, the ... life science community, recognizes the 9 th Annual ... the value of IT technologies in improving our health ... is one of the world,s most vibrant ... EHRs to mobile health applications to genomic testing to ...
(Date:9/16/2014)... cell phones to cars and flashlights, batteries play ... technology companies constantly are seeking ways to improve ... time using a water-based solution, researchers at the ... more efficient nuclear battery that could be used ... source in automobiles and also in complicated applications ...
(Date:9/16/2014)... BlueInGreen® , a water quality company offering ... gases into liquids, announced the addition of ... firm to its sales network. H2Flow will promote ... wastewater applications in the Canadian provinces of Ontario ... and serves Quebec and Ontario markets for water, ...
(Date:9/16/2014)... , Sept. 16, 2014  Donald Fresne, President and CEO ... Stephan Vagner , PhD to its Scientific Advisory Committee. ... Toulouse, France , performed research at Embl ... and at Inserm, the French institute of health and medical ... both at the Curie Institute, Orsay, France ...
Breaking Biology Technology:Biocom Recognizes National Health IT Week 2BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2
... , SAN FRANCISCO, Nov. 17 Merriman ... lead placement agent in PolyMedix Inc.,s (OTC Bulletin Board: PYMX) ... units, which were priced at $1.00 per unit, consist of ... warrant to purchase 0.30 of a share of PolyMedix common ...
... , ... that a new market research report is available ... A Global Market Intelligence Report , ... a key discipline operating on the forefront of ...
... Hungary, Nov. 17 Hungarian drug producer Biropharma and ... connection American BioSciences Inc. and its partner Mate Hidvegi ... Avemar, a dietary supplement being used in cancer treatment ... two different sets of compounds hence the qualities of ...
Cached Biology Technology:Merriman Curhan Ford Acted as Lead Placement Agent in PolyMedix's $20.7 Million Equity Financing 2Reportlinker Adds Bioinformatics - A Global Market Intelligence Report 2Reportlinker Adds Bioinformatics - A Global Market Intelligence Report 3Reportlinker Adds Bioinformatics - A Global Market Intelligence Report 4Reportlinker Adds Bioinformatics - A Global Market Intelligence Report 5Reportlinker Adds Bioinformatics - A Global Market Intelligence Report 6Reportlinker Adds Bioinformatics - A Global Market Intelligence Report 7Hungarian Cancer Formula Producer Questions U.S. Introduction of AveUltra 2
(Date:9/16/2014)... the Exxon Valdez spilled 11 million gallons of oil ... up another giant oil spill in the Gulf of ... the Journal of Consumer Research , news coverage ... instead of catalyzing changes in the way fossil fuels ... media coverage of these two events helped to resolve ...
(Date:9/16/2014)... season of bounty. Fungi of dizzying variety erupt from ... search of elusive but delectable wild mushrooms. Part of ... hunt, and their mysterious not-quite-meat, not-quite-vegetable qualities that belie ... you are eating known to science? , The Fungi ... some estimates range up to 10 million species, only ...
(Date:9/15/2014)... INDIANAPOLIS -- Adding a common epilepsy drug to a ... fewer side effects. Moreover, the combination can reduce the ... to a team of pain researchers at Indiana University. ... patients with neuropathic pain, a difficult-to-treat condition often felt ... tissue damage. , "There is a huge unmet need ...
Breaking Biology News(10 mins):Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 3IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
... crawls onto your lips while you sleep, drawn by the ... your blood. And if that,s not insult enough, it promptly ... Now Jean-Paul Paluzzi, a PhD candidate in biology ... to prevent the insects from leaving their messy calling card ...
... effective way of tackling global warming despite emitting small amounts ... Research led by the University of Edinburgh suggests that plant ... Earth,s emissions of methane which is considered to be about ... The results contrast with a previous scientific study which ...
... ANAHEIM, CA: Could organic labels lead you to overeat? ... organic snack has a lot fewer calories than it really ... Biology conference in Anaheim, Calif. They showed that people ... snack contained 40% fewer calories than the same cookies that ...
Cached Biology News:The kiss of death: Research targets lethal disease spread by insect that bites lips 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: